Navigation Links
Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
Date:12/13/2007

preclinical study to evaluate indiplon administration during the

third trimester of pregnancy.

"While we are disappointed in the FDA action, we will accept the FDA's offer to discuss the applications via a meeting or telephone conference in order to clarify and determine the next steps required," said Gary A. Lyons, President and CEO of Neurocrine.

About Neurocrine

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. The product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, endometriosis, irritable bowel syndrome, pain, and diabetes. Indiplon was licensed from DOV Pharmaceutical in 1998. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties relating to Neurocrine's indiplon program that could cause actual results to differ materially from those indicated in the forward-looking statements. Specifically, the risks and uncertainties the Company faces with respect to its indiplon program include, but are not limited to; risk that the Company will not be able to address issues and or requests set forth in the action letter from the FDA in a timely manner if at all; risk that the Company will not be able to address issues and or requests set forth in the action letters from the FDA in a manner acceptable to the FDA if at all; the risk that FDA may reject any future indiplon regulatory filings or find them incomplete or insufficient; risk that indiplon approval and subsequent commercialization may be significantly delayed; and the other risks described in Neurocrine's annual report on Form 10-K for the year ended Dec
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
3. Neurocrine Biosciences to Present at the Bear Stearns Healthcare Conference
4. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
5. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
7. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
8. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
9. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... 16 Exiqon today announces,the adoption of the ... the company,s commitment to expanding its business to ... guide treatment,decisions in oncology., Exiqon is pleased ... for their,clinical laboratory diagnostics business, Exiqon Diagnostics. This,progressive ...
... Oct. 16 Gaining a first-cycle,approval for a ... $640,million in incremental revenue on average, according to ... of PAREXEL International (Nasdaq: PRXL ),and leading ... device industries. According to the PAREXEL Consulting,analysis, 60 ...
... of carbon nanotubessorted by centrifuge for lengthmaterials scientists ... (NIST) have made some of the most precise ... mats of nanotubes become transparent, conducting sheets. Their ... relatively homogeneousnot overly short, but uniform in length ...
Cached Biology Technology:Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc. 2Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc. 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5Paperwork: Buckypapers clarify electrical, optical behavior of nanotubes 2
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... or simply cli-fi, is a newly coined term for novels ... New research from University of Copenhagen shows how these fictions ... the potential consequences of climate change and imagine other living ... data on changes in the atmosphere; it is also a ... books we read and the films we see. And there ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... (May 23, 2008) A study led by Gregg ... Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, ... the direct thrombin inhibitor bivalirudin during primary angioplasty had ... rate of major bleeding, and a lower mortality rate ...
... May 22, Shire plc (LSE: SHP)(NASDAQ: SHPGY ... High Court approved,the scheme of arrangement between Shire ... The scheme, which becomes effective on 23 May ... Limited (LSE: SHP,NASDAQ: SHPGY) becoming the new holding ...
... international team of scientists surveying the waters of the ... has discovered for the first time high levels of ... raising concern for marine ecosystems from Canada to Mexico. ... research vessel, also discovered that this corrosive, acidified water ...
Cached Biology News:Findings released from 1 of the largest percutaneous coronary intervention trials ever 2Court Approves Scheme of Arrangement 2Court Approves Scheme of Arrangement 3Pacific coast turning more acidic 2Pacific coast turning more acidic 3
... When Ambion introduced the highly potent TURBO DNase ... new standard was set in DNA removal capabilities. ... DNase I that is much more efficient than ... amounts of unwanted DNA. TURBO DNase binds DNA ...
...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: